Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics
Renovaro Inc. (NASDAQ:RENB) announced its corporate rebranding to Lunai Bioworks, Inc., reflecting its strategic focus on AI-powered biodefense, drug discovery, and advanced diagnostics. The company's transformation follows its merger with BioSymetrics, which brought established partnerships with major pharmaceutical companies including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
The company's enhanced platform leverages multimodal AI for real-time biological signal analysis, combining early detection, patient stratification, and therapeutic targeting. The stock will continue trading under the ticker symbol RENB on Nasdaq until further notice.
Renovaro Inc. (NASDAQ:RENB) ha annunciato il rebranding aziendale in Lunai Bioworks, Inc., a testimonianza del nuovo orientamento strategico verso la biodefesa potenziata dall'IA, la scoperta di farmaci e diagnostica avanzata. La trasformazione societaria segue la fusione con BioSymetrics, che ha portato con s茅 collaborazioni consolidate con grandi aziende farmaceutiche tra cui Janssen, Pfizer, Merck, Supernus Pharma e Deerfield Cures.
La piattaforma potenziata sfrutta l'IA multimodale per l'analisi in tempo reale dei segnali biologici, integrando rilevamento precoce, stratificazione dei pazienti e identificazione di target terapeutici. Le azioni continueranno a essere negoziate con il ticker RENB sul Nasdaq fino a nuovo avviso.
Renovaro Inc. (NASDAQ:RENB) anunci贸 su cambio de marca corporativa a Lunai Bioworks, Inc., reflejando su enfoque estrat茅gico en biodefensa impulsada por IA, descubrimiento de f谩rmacos y diagn贸stico avanzado. La transformaci贸n de la compa帽铆a sigue a su fusi贸n con BioSymetrics, que aport贸 alianzas consolidadas con grandes farmac茅uticas como Janssen, Pfizer, Merck, Supernus Pharma y Deerfield Cures.
La plataforma mejorada aprovecha IA multimodal para el an谩lisis en tiempo real de se帽ales biol贸gicas, combinando detecci贸n temprana, estratificaci贸n de pacientes y orientaci贸n terap茅utica. Las acciones seguir谩n cotizando bajo el s铆mbolo RENB en Nasdaq hasta nuevo aviso.
Renovaro Inc. (NASDAQ:RENB)鞚�(電�) 旮办梾氇呾弓鞚� Lunai Bioworks, Inc.搿� 氤�瓴巾暅雼り碃 氚滍憸頄堨溂氅�, 鞚措姅 鞚戈车歆�電� 旮半皹鞚� 靸濍氚╈柎, 鞁犾暯 氚滉荡 氚� 觳嫧 歆勲嫧鞐� 雽�頃� 鞝勲灥鞝� 歆戩鞚� 氚橃榿頃╇媹雼�. 鞚措矆 氤�頇旊姅 BioSymetrics鞕�鞚� 頃╇硲鞐� 霐半ジ 瓴冹溂搿�, Janssen, Pfizer, Merck, Supernus Pharma, Deerfield Cures 霌� 欤检殧 鞝滌暯靷摛瓿检潣 旮办〈 韺岉姼雱堨嫮鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
臧曧檾霅� 頂岆灚韽检潃 雼れ 氇嫭 AI毳� 頇滌毄頃� 靸濍頃欖爜 鞁犿樃毳� 鞁れ嫓臧勳溂搿� 攵勳劃頃橂┌, 臁瓣赴 韮愳, 頇橃瀽 旄淀檾(patient stratification) 氚� 旃橂 響滌爜頇旊ゼ 瓴绊暕頃╇媹雼�. 欤检嫕鞚� 氤勲弰 瓿奠臧� 鞛堨潉 霑岅箤歆� 雮橃姢雼レ棎靹� RENB 韹办护搿� 瓿勳啀 瓯半灅霅╇媹雼�.
Renovaro Inc. (NASDAQ:RENB) a annonc茅 son rebranding corporate en Lunai Bioworks, Inc., refl茅tant son orientation strat茅gique vers la biodefense pilot茅e par l'IA, la d茅couverte de m茅dicaments et le diagnostic avanc茅. Cette transformation fait suite 脿 la fusion avec BioSymetrics, qui a apport茅 des partenariats 茅tablis avec de grands groupes pharmaceutiques tels que Janssen, Pfizer, Merck, Supernus Pharma et Deerfield Cures.
La plateforme am茅lior茅e exploite une IA multimodale pour l'analyse en temps r茅el des signaux biologiques, combinant d茅tection pr茅coce, stratification des patients et ciblage th茅rapeutique. L'action continuera d'锚tre n茅goci茅e sous le symbole RENB sur le Nasdaq jusqu'脿 nouvel ordre.
Renovaro Inc. (NASDAQ:RENB) gab bekannt, dass sich das Unternehmen in Lunai Bioworks, Inc. umbenennt, um seinen strategischen Fokus auf KI-gest眉tzte Biodefense, Wirkstoffforschung und fortschrittliche Diagnostik zu unterstreichen. Die Umstrukturierung folgt der Fusion mit BioSymetrics, die etablierte Partnerschaften mit gro脽en Pharmaunternehmen wie Janssen, Pfizer, Merck, Supernus Pharma und Deerfield Cures einbrachte.
Die erweiterte Plattform nutzt multimodale KI zur Echtzeitanalyse biologischer Signale und vereint Fr眉herkennung, Patientenstratifizierung und therapeutische Zielbestimmung. Die Aktie wird bis auf Weiteres unter dem Tickersymbol RENB an der Nasdaq gehandelt.
- Strategic partnerships with major pharmaceutical companies validate their proprietary platforms
- Enhanced diagnostic capabilities using multimodal AI for real-time biological signal analysis
- Integrated platform combining early detection, patient stratification, and therapeutic targeting
- Expanded capabilities in translational analytics, in vivo modeling, and machine vision
- Rebranding may cause temporary market confusion and recognition challenges
- Integration of merged entities could present operational challenges
Insights
Renovaro's rebrand to Lunai Bioworks signals strategic pivot toward AI-powered biodefense and drug discovery, leveraging recent BioSymetrics acquisition for pharmaceutical partnerships.
This corporate name change from Renovaro to Lunai Bioworks represents more than simple rebranding鈥攊t signals a strategic shift toward integrating artificial intelligence with biotechnology across three high-value domains: biodefense, drug discovery, and advanced diagnostics. The timing is particularly significant following their BioSymetrics merger, which brought established partnerships with pharmaceutical giants including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
The company's technological capabilities now span translational analytics, in vivo modeling, and machine vision鈥攅ssential components for accelerating biomarker discovery in neurology and infectious disease. Their diagnostics platform applies multimodal AI to biological data interpretation, potentially shortening development timelines and improving precision in treatment selection.
What's most compelling is how this positions Lunai at the intersection of three rapidly growing markets: the biodefense sector (critical in post-pandemic planning), AI-accelerated drug discovery (which can reduce traditional development timelines by years), and precision diagnostics (enabling personalized medicine approaches). This strategic alignment with current biotechnology trends could enhance their competitive positioning, particularly if they can successfully integrate the computational strengths from BioSymetrics with their existing biological expertise.
LOS ANGELES, CALIFORNIA / / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered biodefense, drug discovery and advanced diagnostics. The new name underscores the Company's commitment to harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities.
Building on a strong North American base, the Company is enhancing collaboration across its research, development, and commercialization teams and aligning resources to support rapid growth. This strategic integration is designed to improve efficiency, accelerate innovation, and position the Company for long-term success in high-impact biomedical markets worldwide.
As part of its recent merger with BioSymetrics, Lunai Bioworks inherits a robust ecosystem of real-world collaborations with leading biopharmaceutical companies, including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. These partnerships have validated the Company's proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Lunai's diagnostic capabilities now extend beyond traditional boundaries, leveraging multimodal AI to decode complex biological signals in real time. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These innovations are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data.
"Our new name, Lunai Bioworks, captures the fusion of intelligence, innovation, and mission that drives us forward," said David Weinstein, CEO of the Company. "By uniting our teams and focusing squarely on AI-driven biodefense and drug discovery, we are building a platform that can deliver breakthrough solutions for some of the world's most pressing health and security challenges."
The name change was approved by the Board of Directors, and the Company's common stock will continue to trade on Nasdaq under its current ticker symbol, RENB, until further notice.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. More information is available in the Company's filings with the SEC.
Contact:
David Weinstein
Chief Executive Officer
[email protected]
SOURCE: Renovaro Biosciences
View the original on ACCESS Newswire
FAQ
Why is Renovaro (NASDAQ:RENB) changing its name to Lunai Bioworks?
Will Renovaro's stock symbol RENB change after becoming Lunai Bioworks?
What major pharmaceutical companies are partnered with Lunai Bioworks (NASDAQ:RENB)?
What are the main focus areas of Lunai Bioworks' AI technology?
Who is the CEO of Lunai Bioworks (formerly Renovaro)?
